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Aim: This study estimated the hepatitis C virus (HCV) prevalence in a population of human immunodeficiency virus (HIV) 
infected pregnant women, compared women who were positive or negative for HCV and described risk factors associated 
with HCV infection.
Materials and Methods: A retrospective, case control study was conducted at the University College Hospital, Ibadan among 
1821 women. Twenty‑six (1.65%) women were HCV positive, 139 (8.83%) were HBsAg positive and 1407 (89.33%) were 
negative for both viruses. Three patients (0.19%) were positive for both viruses. These patients, i.e., the HBsAg positive 
women and 246 women with no result, for either virus were excluded from analysis. Data from 1433 pregnant women is 
presented. Chi square test and student’s t‑test examined associations, with level of significance set at P < 0.05.
Results: Overall, the mean age of the HCV positive women was lower (26.77 ± 6.53 vs. 28. 95 years ± 5.33; P = 0.04), 
most women had attained primary (28.49%) or secondary (42.44%) education, over 90% were married and heterosexual 
sex (88.67%) was the most likely risk for HIV. HCV prevalence was higher in the lower age groups (5% in the ≤ 19 years 
group, P = 0.021). The coinfected had more unmarried women (3.6% vs. 1.7%; P = 0.164) and more likely to indicate blood 
transfusion as a risk factor for HIV (6.2%; P = 0.34).
Conclusion: Only age showed any significant association with HCV infection. Lack of identifiable risk factors sum up 
challenges for developing screening strategies in sub‑Saharan Africa. Further studies will identify factors facilitating HCV 
transmission in the region.
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Introduction
Hepatitis C (HCV), a blood borne virus, was identified in 
1989. It is a small, enveloped, single‑stranded, positive 
sense RNA virus in the flaviviridae family.[1] It is a major 
global public health problem affecting 3% of the world 
population, i.e., 170 million people globally.[2] In Nigeria, 
the estimated prevalence of HCV infection varies widely 
(0.4–14.7%) depending on the sub‑population being 
considered.[3‑11] HCV is important because it predisposes 
to eventual development of liver fibrosis, as well as 
hepatocellular carcinoma.[12]
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The main modes of transmission of Hepatitis C include 
intravenous drug use,[13,14] unsafe blood and blood products, 
risky sexual behaviour[15] and vertical transmission.[16] Many of 
these modes of transmission are similar to those of HIV, leading 
to coinfection.[17,18] The result is that of the 40 million people 
living with the human immunodeficiency virus type‑1 (HIV); 4.5 
million of these are estimated to be infected with hepatitis C 
as well.[19] Some studies have established that HIV coinfection 
accelerates the progression of HCV infection and vice‑versa.[20] 
In addition, although the mechanism is unclear, several studies 
have reported a higher risk of vertical transmission of HCV in 
HCV/HIV coinfected women.[16,21,22] Previous studies have shown 
that coinfection with HIV and HCV increases the transmission 
risk of HIV from the mother to her baby.
The average rate of Mother‑to‑child transmission (MTCT) 
of HCV is 5% to 6%.[23] The timing and route by which HCV 
passes from the mother to child, and the host defense 
mechanisms that govern this transmission, remain poorly 
understood. Clinical risk factors for MTCT are similar to 
those seen in HIV.[21] Although several risk factors for vertical 
transmission have been identified, none are modifiable and 
there are currently no interventions available to prevent such 
transmission.[23] Finally, treatment of HCV during pregnancy 
has safety issues.[16] Ribavarin has been labeled as a Food and 
Drug Association (FDA) pregnancy category X drug, whereas 
pegylated IFN‑α is an FDA pregnancy category C drug.[24]
In sub‑Saharan Africa, coinfection with HCV and HIV is of 
particular concern. This is because the high prevalence 
of HIV infection and increasing access to life‑prolonging 
antiretroviral therapy in sub‑Saharan Africa, liver disease 
is expected to emerge as a major cause of morbidity and 
mortality among HIV‑infected persons, especially those 
co‑infected with hepatitis.[25]
The objective of this study was to estimate the prevalence of 
HCV infection in a large population of HIV‑infected pregnant 
women. We also compared the characteristics of the HCV 
positive and HCV negative women with a view to describing 
possible risk factors associated with HCV infection in this 
group of pregnant women.
Materials and Methods
The University College Hospital Ibadan offers prevention of 
mother‑to‑child transmission (PMTCT) services supported by 
the Government of Nigeria and the acquired immunodeficiency 
syndrome (AIDS) Prevention Initiative in Nigeria (APIN) 
program. HIV‑positive pregnant women access these services 
having being referred from the UCH antenatal clinic, and 
other clinics in the region. PMTCT services provided include 
antiretroviral therapy for PMTCT, infant feeding counseling 
and family planning counseling. In addition, women are 
monitored by periodic assay of CD4 count and viral load. 
The program maintains an electronic database of the 
records, including laboratory results, of all patients enrolled 
between January 1st 2006 and 31st December 2013; during 
this period, 1821 women registered for care at the PMTCT 
unit of the hospital. Variables recorded at the first clinic 
visit include sociodemographic characteristics, possible 
risk factors for HIV acquisition, CD4 counts, viral load and 
hepatitis B and C status. These baseline laboratory testing 
are conducted using third‑generation enzyme‑linked immune 
absorbent assay (ELISA) for detection of hepatitis B surface 
antigen (HBsAg) and testing for HCV antibodies (anti‑HCV) 
using third‑generation assays. Only those with HIV 
monoinfection or HIV/HCV coinfection were included in the 
review. A retrospective case‑control study was conducted 
among those with HIV/HCV coinfection as cases and those 
with HIV monoinfection as controls.
The baseline characteristics of HCV‑infected and uninfected 
pregnant women were analyzed. Data was entered 
and analysed using the Statistical Package for Social 
Sciences (SPSS Inc, Chicago, IL, USA, version 15). Continuous 
variables were presented as mean and standard deviation 
whereas categorical variables were presented as frequencies 
or percentages. Associations between categorical variables 
were investigated using Chi‑square test whereas student’s 
t‑test was used to test for significant difference in continuous 
variables, with level of significance set at P < 0.05.
Results
During the study period, 1821 women presented for care. 
Two hundred and forty six (246) of the women had no 
available result for screening tests for either HBV or HCV, 
and hence were excluded from the analysis. Table 1 shows 
the distribution of the patients according to hepatitis status 
over the years under consideration. The number of new 
HIV‑positive pregnant women seen at the clinic is noted to 
have declined gradually over the years. The prevalence of 
HCV is noted to reduce in a similar pattern.
Overall 26 (1.65%) women were positive for HCV, 139 (8.83%) 
were positive for HBsAg and 1407 (89.33%) were negative for 
both HBV and HCV. Three patients (0.19%) were positive for 
both HBV and HCV. These patients and the HBsAg positive 
pregnant women were also excluded from further analysis 
because the presence of HBV could confound the results.
In the final analysis, a total of 1433 pregnant women were 
eligible for inclusion in the study [Figure 1].
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Table 2 shows the distribution of the sociodemographic 
characteristics. Overall, the mean age of the patients 
was 29.16 ± 7.14. The mean age of the HCV‑positive 
and HCV‑negative women was 26.77 years ± 6.53 and 
28.95 years ± 5.33, respectively (P = 0.04). Most of the 
women were of low socioeconomic status and had attained 
only primary or secondary level of education. Over 90% were 
married and had heterosexual sex as the most likely route 
of HIV transmission.
The prevalence of HCV was higher in the lower age groups 
with 5% and 4% prevalence reported in the 19 years and below 
age group and the 20–24 years age group, respectively. The 
difference in HCV prevalence in the different age groups was 
statistically significant.
The pattern of occupation and level of education was 
similar among HIV/HCV coinfected and HIV monoinfected 
women. A large proportion of the patients were involved 
with low‑skilled employment or trading. Most of the HCV 
positive women were in the low skilled groups. Finally, 
the coinfected group had more unmarried women and 
were more likely to have indicated blood transfusion as 
a risk factor for HIV. However, these differences were not 
statistically significant. Two patients admitted to a history 
of intravenous drug use, however, neither was reported as 
being HCV positive.
Discussion
The prevalence of HIV/HCV coinfection in our population 
of HIV‑infected pregnant women is low. Age was the only 
identifiable risk factor for HCV in this cohort. Intravenous 
Table 1: Distribution of hepatitis status over the years
Year Total Hepatitis Hepatitis Hepatitis Hepatitis
B/C negative C positive B positive B&C positive
No (%) No (%) No (%) No (%) No (%)
2006 315 (20.0) 285 (90.5) 7 (2.2) 23 (7.3) 0 (0.0)
2007 379 (24.1) 330 (87.1) 7 (1.8) 41 (10.8) 1 (0.26)
2008 204 (12.94) 181 (88.7) 6 (2.9) 17 (8.3) 0 (0.0)
2009 185 (11.74) 172 (93.0) 2 (1.1) 11 (5.9) 0 (0.0)
2010 166 (10.53) 144 (86.7) 3 (1.8) 18 (10.8) 1 (0.6)
2011 142 (9.02) 129 (90.8) 1 (0.7) 12 (8.5) 0 (0.0)
2012 127 (8.05) 115 (90.6) 0 (0.0) 11 (8.7) 1 (0.79) 
2013 57 (3.62) 51 (89.5) 0 (0.0) 6 (10.5) 0 (0.0)
Total 1575 (100.0) 1407 (89.33) 26 (1.65%) 139 (8.83) 3 (0.19)
Table 2: Sociodemographic characteristics of participants
Year Total Hepatitis Hepatitis P
C positive B/C negative
No (%) No (%) No (%)
Age group
≤19 years 40 (2.82) 2 (5.0) 38 (95.0) 0.021
20-24 years 247 (17.39) 10 (4.0) 237 (96.0)
25-29 492 (34.65) 6 (1.2) 486 (98.8)
30-34 426 (30.0) 3 (0.7) 423 (99.3)
35-39 172 (12.11) 4 (2.3) 168 (97.7)
≥40 years 43 (3.03) 1, (2.3) 42 (97.7)
Occupation
Unemployed/trainee
/student 79 (8.54) 3 (3.8) 76 (96.2) 0.642
Low skilled/farming 278 (30.05) 6 (2.16) 272 (97.84)
Trading 405 (43.78) 10 (2.47) 395 (97.53)
Civil servant (junior) 29 (3.14) 0 (0) 29 (100.0)
Civil servant (senior) 61 (6.6) 2 (3.28) 59 (96.72)
Housewife 68 (7.35) 0 (0.0) 68 (100.0)
Uniformed 5 (0.54) 0 (0.0) 5 (100.0)
Level of education 
None 108 (7.81) 0 (0.0) 108 (100.0) 0.756
Primary school 394 (28. 49) 8 (2.0) 386 (98.0)
Secondary school 587 (42.44) 12 (2.0) 575 (98.0)
Tertiary level 294 (21.26) 5 (1.7) 289 (98.3)
Marital status
Married 1299 (92.06) 22 (1.7) 1277 (98.3 0.164
Not married 112 (7.94) 4 (3.6) 108 (96.4)
Risk factor for HIV
Heterosexual sex 892 (88.67) 22 (1.8) 870 (97.97) 0.336
Transfusion 11 (1.09) 1 (6.2) 10 (90.91)
Heterosexual/transfusion 41 (4.08) 2 (3.7) 39 (95.12)
Unknown 60 (5.96) 1 (1.7) 59 (98.3)
IVDU 2 (0.2) 0 (0.0) 2 (100.0)
Total number of pregnant women 
enrolled in the service between 1st
January 2006 to 31st December 2013 
1821
HIV infected with results Hep 
B and Hep C virus screen
1575
HIV-infected with 
no Hep B/C results
246
HIV-infected with
- Hep B 
coinfection 139
- Hep Band C 
coinfection 3
HIV infected with or without 
HepC coinfection
1433
HIV infected without 
Hep C coinfection
1407
HIV infected with 
Hep C coinfection
26
Figure 1: Flow diagram of pregnant women enrolled in the study
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drug use, which features prominently in most series, was not 
a risk factor in this group of pregnant women.
Worldwide, HCV prevalence in pregnant women has been 
estimated to be approximately 1%.[26] The HCV coinfection 
rate of 1.65% in this cohort of HIV positive women is in the 
range of 1.5% and 2.4%, respectively, reported among HIV 
positive pregnant women in Lagos by Ezechi et al.[3] and Zeba 
et al. in Ouagadougou.[27] It is, however, lower than the rate 
of 5.3% reported by Chasela et al. from Malawi,[28] and much 
lower than 29.69% reported by Seisdedos et al. from Spain[29] 
among HIV‑positive pregnant women. In the general obstetric 
population (from various parts of Nigeria), rates of hepatitis 
C prevalence of 2.7%, 2.6%, 3.6% and 0.4% have been reported 
from Osogbo,[9] Enugu,[30] Benin[11] and Calabar,[6] respectively. 
In the adult HIV‑positive population (also in Nigeria), rates 
of 11.3%, 2.3%, 3.1% and 4.8% have been reported from Jos,[4] 
Lagos[31] and Ibadan,[10] respectively.
Some of the reasons given for these wide variations in 
prevalence include the screening algorithms adopted. It 
has been suggested that most HCV prevalence estimates 
from sub‑Saharan Africa based on screening systems 
without supplemental testing are overestimates.[28] These 
supplemental testing include confirmatory tests such 
as nucleic acid and test for HCV RNA or Recombinant 
immunoblot assay (RIBA).[2] Studies using supplemental 
testing have reported lower prevalence estimates.[32,33] These 
authors have noted that continued HCV screening without 
supplemental confirmatory testing of blood donations 
could result in discarding uninfected blood. In addition, the 
disclosure of test results may cause unnecessary despair 
to those misdiagnosed and the permanent withdrawal of 
uninfected donors from the small donor pool. There is, thus, 
a need for increased focus on improving the HCV testing 
algorithms in sub‑Saharan African.
Apart from a higher prevalence of HCV in the young 
age groups, there were no remarkable differences in 
the sociodemographic characteristics between the HIV 
monoinfected and HIV/HCV coinfected pregnant women. 
Age has been argued to be a major factor in HCV studies. 
However, in contrast to our cohort, a higher prevalence of 
infection in older individuals has been reported.[34,35] It has 
been suggested that the reported higher prevalence of HCV 
in older individuals may be due to the prolonged period of 
incubation of the virus.[1] In a study conducted in 2000 in 
Egypt, Abdel‑Aziz found anti‑HCV antibody prevalence to 
increase sharply with increasing age, with persons currently 
or previously married more likely to be seropositive than 
those who never married.[36] In our study, while the possible 
reason for the higher prevalence in the younger age groups 
is not clear, the unmarried group actually had a higher 
prevalence of HCV positive women. The difference observed 
in marital status was, however, not statistically significant.
In most series the main route of acquiring HCV in pregnant 
mothers was intravenous drug use, whereas previous blood 
transfusion was a risk factor in up to 11% of cases.[22,37,38] Only 
2 patients admitted to a history of intravenous drug use 
in the group of pregnant women we studied. Intravenous 
drug use is uncommon in this part of the world.[6] However, 
the group of HIV‑positive women who reported previous 
blood transfusion as a risk factor for HIV infection had a 
higher prevalence of HCV infection in our cohort. Globally, 
transfusion‑associated infection was a predominant risk 
factor before HCV testing became available.[7] Indeed, in 
communities that have implemented routine testing of 
donors, it has been virtually eliminated. However, in other 
communities, receipt of unsafe blood and blood products 
remain an important source of infection.[7] A contributory 
factor is the continued use of commercial donors to 
supplement blood supplies by some countries.[32]
With the exception of age, other putative risk factors evaluated 
in this study showed no significant association with anti‑HCV 
seropositivity. The risk factors for HCV infection may be 
unidentified in a significant proportion of patients in many 
parts of the world. In some studies, risk factors accounting for 
infection remain unknown in 10–40% of patients, with acute or 
chronic Hepatitis C.[39,40] Indeed in 60 of the patients we studied, 
the risk factors were unknown. These findings pose major 
implications for developing strategies for HCV screening.[7] 
Individuals infected with the virus with no identifiable risk 
factors sum up the problems associated with HCV studies in 
the sub‑saharan Africa region.[6] This finding, therefore, suggests 
the need for further studies that would evaluate factors that 
may facilitate HCV transmission in the region.
This study has several limitations. First, the risk factors 
for viral hepatitis acquisition were not directly evaluated. 
Instead, the risk factors for HIV infection were used as proxy 
on account of the similarity in modes of transmission of 
both viruses. Second, plasma HCV‑RNA was not quantified 
in patients who had anti‑HCV, making it impossible to 
distinguish active HCV infection from spontaneously cleared 
infection. Third, this was a retrospective study. However, data 
collection and retrieval via an electronic platform afforded a 
robust information collection.
Conclusion
In conclusion, the seroprevalence of anti‑HCV in the 
population of HIV positive Nigerian pregnant women 
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evaluated in this report is 1.65%. The risk factors associated 
with anti‑HCV seropositivity are largely obscure, and this calls 
for more studies into the epidemiology of HCV infection to 
develop effective strategies for screening.
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